IL314199A - History of azaindole and their use as ERK kinase inhibitors - Google Patents

History of azaindole and their use as ERK kinase inhibitors

Info

Publication number
IL314199A
IL314199A IL314199A IL31419924A IL314199A IL 314199 A IL314199 A IL 314199A IL 314199 A IL314199 A IL 314199A IL 31419924 A IL31419924 A IL 31419924A IL 314199 A IL314199 A IL 314199A
Authority
IL
Israel
Prior art keywords
kinase inhibitors
erk kinase
azaindole derivatives
azaindole
derivatives
Prior art date
Application number
IL314199A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agv Discovery
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agv Discovery, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Montpellier filed Critical Agv Discovery
Publication of IL314199A publication Critical patent/IL314199A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL314199A 2022-01-14 2023-01-13 History of azaindole and their use as ERK kinase inhibitors IL314199A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors
PCT/EP2023/050692 WO2023135233A1 (en) 2022-01-14 2023-01-13 Azaindole derivatives and their use as erk kinase inhibitors

Publications (1)

Publication Number Publication Date
IL314199A true IL314199A (en) 2024-09-01

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314199A IL314199A (en) 2022-01-14 2023-01-13 History of azaindole and their use as ERK kinase inhibitors

Country Status (16)

Country Link
US (3) US11827637B2 (https=)
EP (2) EP4212531A1 (https=)
JP (1) JP2025502377A (https=)
KR (1) KR20240134887A (https=)
CN (1) CN118541370A (https=)
AR (1) AR128267A1 (https=)
AU (1) AU2023207276A1 (https=)
CA (1) CA3242894A1 (https=)
CL (1) CL2024002070A1 (https=)
CO (1) CO2024008809A2 (https=)
IL (1) IL314199A (https=)
JO (1) JOP20240157A1 (https=)
MX (1) MX2024008629A (https=)
TW (1) TW202334147A (https=)
UA (1) UA130477C2 (https=)
WO (1) WO2023135233A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012386A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
CN121511244A (zh) * 2023-07-12 2026-02-10 Agv探索公司 (s)-1-(1-(3-氯苯基)-2-(二甲氨基)乙基)-4-(5-吗啉代-1h-吡咯并[2,3-b]吡啶-3-基)吡啶-2(1h)-酮的盐，其制备及其作为erk激酶抑制剂的用途
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
WO2026064271A1 (en) 2024-09-23 2026-03-26 Fmc Corporation Substituted bicyclic amide derivatives as herbicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2012094313A1 (en) 2011-01-04 2012-07-12 Kinentia Biosciences Llc Pyrazole derivatives as erk inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
EP3247353A4 (en) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
BR112021009430A2 (pt) * 2018-11-16 2021-08-17 California Institute Of Technology inibidores de erk e usos dos mesmos
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
US12421231B2 (en) 2025-09-23
UA130477C2 (uk) 2026-02-25
WO2023135233A1 (en) 2023-07-20
JP2025502377A (ja) 2025-01-24
TW202334147A (zh) 2023-09-01
CO2024008809A2 (es) 2024-08-08
CN118541370A (zh) 2024-08-23
AU2023207276A1 (en) 2024-08-01
AR128267A1 (es) 2024-04-10
EP4212531A1 (en) 2023-07-19
US11827637B2 (en) 2023-11-28
US20260042758A1 (en) 2026-02-12
US20230227451A1 (en) 2023-07-20
US20240308997A1 (en) 2024-09-19
EP4463453A1 (en) 2024-11-20
CA3242894A1 (en) 2025-02-28
CL2024002070A1 (es) 2024-11-29
KR20240134887A (ko) 2024-09-10
MX2024008629A (es) 2024-08-19
JOP20240157A1 (ar) 2024-07-14

Similar Documents

Publication Publication Date Title
IL314199A (en) History of azaindole and their use as ERK kinase inhibitors
EP4077328A4 (en) PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS
IL326350A (en) Benzopyridinones and benzopyrimidinones as PI3K inhibitors
SG11202101148UA (en) PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES
SI4084778T1 (sl) Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
SMT201500200B (it) Derivati di imidazo[1,2-a]piridina come inibitori delle chinasi fgfr per l'uso in terapia
PL4146658T3 (pl) Nowe makrocykliczne inhibitory kinazy lrrk2
IL207865A0 (en) Pim kinase inhibitors and methods of their use
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
IL285127A (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
IL304728A (en) cdk2 inhibitors and methods of using them
EP4370124A4 (en) PI3KA INHIBITORS AND METHODS OF USE THEREOF
IL321319A (en) Compounds and preparations as c-kit kinase inhibitors
EP3907225A4 (en) COMPOUNDS DERIVED FROM IMIDAZOPYRIDINE AND THEIR USE
IL305931A (en) Pyrazolopyridine derivatives and their uses
IL326424A (en) Pharmaceutical compounds and preparations as C-KIT kinase inhibitors
EP4219456A4 (en) CSF1R KINASE INHIBITORS AND USE THEREOF
PT4084778T (pt) Formulações de inibidores de quinase amorfas e métodos de utilização das mesmas
HK40114100A (en) Azaindole derivatives and their use as erk kinase inhibitors
IL307678A (en) Methods of administering certain VMAT2 inhibitors
HUE072220T2 (hu) VMAT2-inhibitorok és alkalmazási eljárások
EP4284371A4 (en) SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS FOR THE THERAPEUTIC USE THEREOF
IL306008A (en) Pyrimidine derivatives are useful as LRRK2 kinase inhibitors
HK40119413A (en) Macrocyclic compounds and use as kinase inhibitors
TWI923653B (zh) 作為ｊａｋ２抑制劑之６-雜芳基氧基苯并咪唑及氮雜苯并咪唑及其醫藥組合物及用途